5-Amino-1MQ – User Manual & Dosage Protocol Guide

5-Amino-1MQ is a small-molecule NNMT (Nicotinamide N-Methyltransferase) inhibitor studied in metabolic research models for its potential influence on cellular energy regulation and adiposity pathways.

Research Applications

• NNMT inhibition studies
• NAD+ pathway modulation research
• Adipocyte metabolism models
• Body composition research
• Metabolic flexibility investigations

Disclaimer: 5-Amino-1MQ is for research and experimental use only and is not FDA-approved for therapeutic use in this context.

Lyophilized Powder

Freeze-dried 5-Amino-1MQ for reconstitution

Oral Capsule (Research Grade)

Pre-measured investigational format

Reconstituted Solution

Injectable research preparation after dilution

Availability may vary by supplier.

5-Amino-1MQ is studied for its ability to:

• Inhibit NNMT enzyme activity
• Influence nicotinamide metabolism
• Affect NAD+ availability
• Modify methylation balance in metabolic models
• Alter adipocyte energy expenditure in preclinical studies

Observed effects are primarily derived from animal and in vitro research models.

Injectable Research Model

Subcutaneous (SC) Administration

Typical range: 5–10 mg

Frequency: Once daily

Notes: Common metabolic research range

Higher-Range Research

Typical range: 10–20 mg

Frequency: Once daily

Notes: Used in some adiposity studies

Oral Research Model

Oral Capsule Administration

Typical range: 50–150 mg

Frequency: Once daily

Notes: Used in animal-equivalent modeled protocols

Note: Human equivalent dosing has not been formally established. Values above reflect commonly reported investigational ranges in research settings.

Initiation Phase

Duration: 1–2 weeks

Purpose: Tolerance and metabolic response evaluation

Active Study Phase

Duration: 6–12 weeks

Purpose: Body composition and metabolic outcome observation

Rest Period

Duration: 2–4 weeks

Purpose: Washout between research cycles

Cycle duration varies depending on research objectives.

Supplies

• Sterile bacteriostatic water
• Sterile syringe
• Alcohol swabs

General Procedure

1. Clean vial stopper with alcohol.
2. Add bacteriostatic water to desired concentration.

• Example: 50 mg vial + 5 mL → 10 mg/mL

1. Swirl gently to dissolve (do not shake).
2. Refrigerate at 2–8°C after reconstitution.
3. Use within 2–4 weeks or per research protocol.

Subcutaneous Injection Model

• Common sites: abdomen, thigh
• Clean site prior to administration
• Inject slowly
• Rotate injection sites

Oral Model

• Administer consistently at the same time daily
• Typically used in fasted metabolic research settings

Lyophilized Powder

Storage: Cool, dry environment

Shelf life: Up to 12 months

Reconstituted Solution

Storage: Refrigerated (2–8°C)

Shelf life: 2–4 weeks

Oral Capsules

Storage: Room temperature, dry environment

Shelf life: Per manufacturer

Protect From:

Light, heat, moisture, and contamination

Discard if the solution becomes cloudy or discolored.

• Research use only
• Not for therapeutic application
• Human safety outside controlled research is not established
• Possible research observations may include:
• Injection-site irritation
• Gastrointestinal discomfort (oral model)
• Headache
• Transient fatigue

Maintain sterile handling techniques at all times.

Keep out of reach of children.

Compound: 5-Amino-1MQ
Category: Metabolic Research / NNMT Inhibitor
Delivery Models: Subcutaneous research model or oral investigational format
Typical Investigational Range:

• Injectable: 5–20 mg daily
• Oral: 50–150 mg daily
  Cycle Framework: 6–12 week study designs
  Storage: Refrigerated after reconstitution